Papulopustular rosacea treated with ivermectin 1% cream: remission of the Demodex mite infestation over the time and evaluation of clinical relapses
Citation: Trave I, Micalizzi C, Cozzani E, Gasparini G, Parodi A. Papulopustular rosacea treated with ivermectin 1% cream: remission of the Demodex mite infestation over the time and evaluation of clinical relapses. Dermatol Pract Concept. 2022;12(4):e2022201. DOI: https://doi.org/10.5826/dpc.1204a201
Accepted: March 3, 2022; Published: October 2022
Copyright: ©2022 Trave et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Competing interests: None.
Authorship: All authors have contributed significantly to this publication.
Corresponding author: Ilaria Trave, Section of Dermatology - Department of Health Sciences, University of Genoa, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy. Tell: 0105555750 Email: firstname.lastname@example.org
Background: Topical ivermectin is an anti-inflammatory and anti-Demodex drug for papulopustular rosacea. Rosacea is a relapsing disease and the time between recurrences should be considered alongside efficacy
Objectives: The aims of this study were to assess the time of first relapse and relapse rates of Demodex mite infestation and papulopustular rosacea
Methods: We conducted a prospective study of subjects affected by different degrees of papulopustular rosacea. Patients that achieved a complete response after treatment were monitored every 4 weeks and up to 32 additional weeks. For each patient, we evaluated recording the time to first relapse and relapse rate of Demodex mite infestation and rosacea.
Results: The overall success rate on Demodex infestation was 87.5%. only 12.5% relapse. Ivermectin leads to complete response in 70% of patients. Median time to relapse was 140 days, the mean time was 152 days. The global success rate was 54.76%.
Conclusions: Topical ivermectin keeps a remission of Demodex infestation and clinical remission for long time. We proposed a twice-weekly ivermectin maintenance therapy to reduce recurrences.